Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altimmune, Inc. - Common Stock
(NQ:
ALT
)
6.230
-0.550 (-8.11%)
Official Closing Price
Updated: 4:15 PM EST, Jan 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Altimmune, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
(ALT) - Analyzing Altimmune's Short Interest
March 22, 2024
Via
Benzinga
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
March 19, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter.
Via
Benzinga
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
March 18, 2024
Via
Benzinga
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
March 15, 2024
Viking Therapeutics just might be an attractive acquisition target for Pfizer.
Via
The Motley Fool
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
March 01, 2024
The Nasdaq is on the cusp of setting a record high.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
February 28, 2024
Via
Benzinga
(ALT) - Analyzing Altimmune's Short Interest
February 14, 2024
Via
Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Via
Benzinga
How Is The Market Feeling About Altimmune?
January 26, 2024
Via
Benzinga
Stocks Start Week On A Hesitant Note
February 26, 2024
Stocks are barely moving to start the week, just one session removed from record highs.
Via
Talk Markets
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
February 26, 2024
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.
Via
Investor's Business Daily
Altimmune Stock Surges, Kerrisdale Remains Short: What You Need To Know
February 26, 2024
Altimmune shares are trading higher Monday despite a lack of company-specific news. Kerrisdale Capital told Benzinga on Monday that the firm is still short Altimmune stock.
Via
Benzinga
TEVA Stock Pops 4% as Teva Receives FDA Approval
February 26, 2024
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.
Via
InvestorPlace
Exposures
Product Safety
Why Is Altimmune (ALT) Stock Up 14% Today?
February 26, 2024
Altimmune stock is rising higher on Monday as ALT investors react to positive news from rival weight loss drugmaker Zealand Pharma.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 26, 2024
Via
Benzinga
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
February 13, 2024
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
Via
InvestorPlace
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
February 13, 2024
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position
Via
Benzinga
Jim Cramer Calls Affirm 'A Winner,' But Not C3.ai: 'I Can't Recommend A Stock With No Earnings'
February 13, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vertiv Holdings Co (NYSE: VRT) is "one of the great per
Via
Benzinga
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 13, 2024
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance.
Via
Benzinga
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
January 25, 2024
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments.
Via
InvestorPlace
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
The 3 Best Biotech Stocks to Buy in January 2024
January 09, 2024
Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks.
Via
InvestorPlace
Harpoon Therapeutics, Heron Therapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session
January 08, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 150 points on Monday. Shares of Harpoon Therapeutics, Inc.(NASDAQ: HARP) rose sharply in pre-market trading....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Obesity Drug-Developer Altimmune Inc Stock?
January 04, 2024
Altimmune, Inc. (NASDAQ: ALT) shares are trading higher Thursday, and the stock has gained more than 140% over the past month.
Via
Benzinga
Coherus BioSciences And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
December 27, 2023
U.S. stock futures were slightly lower this morning, with the Dow Jones futures falling around 5 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
December 26, 2023
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 40 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
December 19, 2023
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &...
Via
Benzinga
Topics
ETFs
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
December 08, 2023
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.